-
-
Why is Circle Internet stock sliding today?
-
New York and New Jersey declare states of emergency, bracing for flooding and outages from nor’easter
-
Exclusive-OpenAI works to understand full scope of agent activity as user data leak emerges
-
New Jersey’s lieutenant governor resigns amid sexual harassment findings
-
Fortinet CFO Christiane Ohlgart sells $8,640 in company stock
-
Goldgroup Mining closes $122 million private placement
-
Most Americans who want to lose weight don’t want to take GLP-1 drugs like Wegovy and Zepbound, new survey says
GLP-1s, or glucagon-like peptide-1 agonist drugs, are seemingly everywhere. In recent years, this class of weight-loss and Type 2 diabetes medication has become not only a household name but inescapable. Shortages have dominated news headlines, and singsong commercials about the best online GLP-1 programs have taken over airwaves. GLP-1s have gone so far as to…
-
Temu spent up to $962 million on ads that helped finance an army of fake creators on Meta platforms, research claims
If you are one of Ya Lili’s 183,000 followers on her “@findgadgetswithme” Instagram account, you may have seen this video she posted recently: A man stands on a sunny beach, dressed only in swim shorts, his back covered in dirt. “This won’t come off!” he shouts as he rubs futilely at the brown filth covering…
-
GLP-1 drugs like Wegovy are all the rage—but people are quitting them too fast to achieve meaningful weight loss, finds 170,000-patient study
As recently as the onset of COVID-19 four years ago, you probably didn’t know what a glucagon-like peptide 1 agonist, or GLP-1 drug, was. But this class of medications, which help people with Type 2 diabetes and obesity lower their blood sugar and promote weight loss, is now a household name. “It’s everywhere,” Dr. Razia…